Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for BioCorRx (BICX) over the last 15 years, with Q3 2025 value amounting to -$915243.0.

  • BioCorRx's Change in Receivables fell 23726.26% to -$915243.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$916723.0, marking a year-over-year decrease of 21001.27%. This contributed to the annual value of -$740.0 for FY2024, which is 9786.36% up from last year.
  • According to the latest figures from Q3 2025, BioCorRx's Change in Receivables is -$915243.0, which was down 23726.26% from $237164.0 recorded in Q4 2024.
  • BioCorRx's Change in Receivables' 5-year high stood at $237164.0 during Q4 2024, with a 5-year trough of -$915243.0 in Q3 2025.
  • Moreover, its 5-year median value for Change in Receivables was $1786.0 (2021), whereas its average is -$46763.9.
  • Per our database at Business Quant, BioCorRx's Change in Receivables skyrocketed by 3370400.0% in 2021 and then crashed by 188413.69% in 2023.
  • Over the past 5 years, BioCorRx's Change in Receivables (Quarter) stood at $168020.0 in 2021, then tumbled by 41.04% to $99070.0 in 2022, then plummeted by 158.34% to -$57801.0 in 2023, then surged by 510.31% to $237164.0 in 2024, then plummeted by 485.91% to -$915243.0 in 2025.
  • Its last three reported values are -$915243.0 in Q3 2025, $237164.0 for Q4 2024, and -$271374.0 during Q3 2024.